At its booth at the Society of Nuclear Medicine meeting, nuclear medicine vendor SMV will feature images from recent clinical studies under way to validate new technologies ranging from artifact correction to high-energy coincidence detection imaging.In
At its booth at the Society of Nuclear Medicine meeting, nuclear medicine vendor SMV will feature images from recent clinical studies under way to validate new technologies ranging from artifact correction to high-energy coincidence detection imaging.
In cardiac imaging, the Twinsburg, OH, company will display the latest studies from its Transmission Attenuation Correction (TAC) sites. The sites are demonstrating the value of using TAC on its own and in conjunction with SMV's Stasis motion correction algorithm and Restore depth-dependent resolution recovery technique.
In the coincidence detection realm, SMV will show images from its Volumetric Coincidence Reconstruction (VCR) option, which received 510(k) clearance in March for the Vision FX-80 fixed 180 dual-head camera (SCAN 4/16/97). SMV is waiting for clearance of VCR for its variable-angle cameras, according to Bill Bishop, vice president of business development. SMV will emphasize VCR image quality enhancements with algorithms such as randoms correction.
On the workstation side, the PowerStation SPX and MPX computers will be displayed, with SMV's new Vision 4.1 software. The software includes increased protocol automation, better edge detection, and the addition of Transient Ischemic Dilitation (TID) to SMV's MultiDim 3-D quantification.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.